Selina M. Luger, MD
she/her/hers
Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Penn Medicine Provider

About me

  • Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: McGill University
  • Residency: Presbyterian University Hospital
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating

458 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

October 2025
great communication.
October 2025
very knowledgeable, professional, and kind.
October 2025
excellent care by dr luger
October 2025
dr. luger explains things so i can understand.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Luger is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Luger SM, Ciccarelli BT. A CHIP off the old (MDS) block , Haematologica, 110: 2025,1898-1899


Kalra LP, Zylyftari S, Blums K, Barthelmes S, Baum H, Meckel S, Heilgeist A, Luger S, Foerch C. Rapid Diagnosis of Intracerebral Hemorrhage in Patients With Acute Stroke by Measuring Prehospital GFAP Levels on a Point-of-Care Device (DETECT) , Neurology, 105: 2025,e213823


Natalie Wuliji, Salene M. W. Jones, Ted Gooley, Aaron T. Gerds, Bruno C. Medeiros, Paul J. Shami, John Galvin, Kehinde Adekola, Selina Luger, Maria R. Baer, David Rizzieri, Tanya M. Wildes, Eunice S. Wang, Mikkael A. Sekeres, Sudipto Mukherjee, Julie Smith, Mitchell Garrison, Kiarash Kojouri, Jacob Appelbaum, Mary-Elizabeth Percival, Brenda M. Sandmaier, Stephanie Lee, Frederick R. Appelbaum, Rayne Rouce, Mohamed L. Sorror; Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia , Blood: 2025


Iacobucci I, Zeng AGX, Gao Q, Garcia-Prat L, Baviskar P, Shah S, Murison A, Voisin V, Chan-Seng-Yue M, Cheng C, Qu C, Bailey C, Lear M, Witkowski MT, Zhou X, Zaldivar Peraza A, Gangwani K, Advani AS, Luger SM, Litzow MR, Rowe JM, Paietta EM, Stock W, Dick JE, Mullighan CG Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features. , Nat Cancer: 2025


Wolfson JA, Grimes AC, Nuño MM, Ramakrishnan S, Dickens DS, Roth ME, Woods W, Adams KS, Alabi T, Beauchemin M, Levine JM, Scialla M, Boayue KB, Kerber CL, Ponce O, Vargas S, Chang GJ, Stock W, Hershman D, Curran E, Advani A, O'Dwyer K, Luger S, Liu JJ, Freyer DR, Sung L, Parsons SK. Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia , JNCI Cancer Spectr, 9: 2025,pkaf033


Talha Badar, Selina M. Luger, Mark R. Litzow Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia , Blood: 2025


Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Bayer RL, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Erba HP, Appelbaum FR. Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia , JCO Oncol Pract: 2025


Chow RD, Velu P, Deihimi S, Belman JP, Youn A, Shah N, Luger SM, Carroll MP, Morrissette JJ, Bowman RL. Persistent post-remission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia , Blood Adv: 2025


Jillella AP, Lee SJ, Altman JK, Luger SM, Tallman MS, Foran JM, Bradshaw D, Law LY, Bryan LJ, Abou Zahr A, Begna KH, Perl AE, Vadakara JJL, Qamar R, Bergan RC, Fisch MJ, Carlos RC, Wagner LI, Kota VK, Litzow MR. Academic Community Partnership in Acute Promyelocytic Leukemia and Early MortalityThe ECOG-ACRIN EA9131 Trial , JAMA Oncol.: 2025


Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C. Evolving racial/ethnic disparities in AML survival in the novel therapy era , Blood Adv, 9: 2025,533-544